Renal Biomarkers Market Report by Biomarker Type (Functional Biomarker, Up-regulated Protein, and Others), Diagnostic Technique (Enzyme-linked Immunosorbent Assay (ELISA), Particle-enhanced Turbidimetric Immunoassay (PETIA), Colorimetric Assay, Chemilumin

The global renal biomarkers market size reached USD 1.4 Billion in 2024. Looking forward, IMARC Group expects the market to reach USD 2.6 Billion by 2033, exhibiting a growth rate (CAGR) of 6.54% during 2025-2033. The increasing public health concerns and its main risk factors, including hypertension, diabetes, and heart diseases, are bolstering the market.

Renal biomarkers are cells, proteins, lipids, microRNAs, genes, metabolites, or proteomic patterns present on a urinalysis. They assist in determining the glomerular filtration rate (GFR) of kidneys to analyze their proper functioning and evaluating pathogenic processes or pharmacological responses to therapeutic interventions. As they also aid in predicting disease progression and computing drug dosage, renal biomarkers find extensive applications in hospitals and diagnostic laboratories across the globe.

Renal Biomarkers Market Trends:

Chronic kidney disease (CKD), non-communicable disease with considerable morbidity and mortality, has gradually become a public health concern globally and its main risk factors are diabetes, hypertension and heart diseases. The increasing number of individuals with CKD represents one of the key factors propelling the growth of the market. Moreover, renal biomarkers, including blood urea nitrogen (BUN), serum creatinine (SCr), urinary albumin/protein and volume excretion, are used in the diagnosis of chronic kidney disease (CKD) and monitoring of the disease. Besides this, there is a growing interest of industry investors in novel single biomarkers and process-specific biomarker panels in human renal diseases around the world. These novel biomarkers provide vital diagnostic and prognostic information and help predict response to the treatment of glomerulopathies, acute kidney injury (AKI), and autosomal dominant polycystic kidney disease (ADPKD). Apart from this, renal biomarkers are becoming accessible and feasible in all-sized laboratories. This, along with the development and integration of genomics, epigenetics, transcriptomics, proteomics, and metabolomics, is positively influencing the market. Some of the other factors, such as the burgeoning healthcare industry, the rising geriatric population, and the increasing number of clinical trials for CKD worldwide, are anticipated to facilitate the growth of the market.

Key Market Segmentation:

IMARC Group provides an analysis of the key trends in each segment of the market, along with the renal biomarkers market forecast at the global, regional, and country levels for 2025-2033. Our report has categorized the market based on the biomarker type, diagnostic technique, and end user.

Breakup by Biomarker Type:

• Functional Biomarker
• Serum Creatinine
• Serum Cystatin C
• Urine Albumin
• Up-regulated Protein
• Neutrophil Gelatinase-Associated Lipocalin (NGAL)
• Kidney Injury Molecule-1
• INTERLEUKIN-18
• Others

Breakup by Diagnostic Technique:

• Enzyme-linked Immunosorbent Assay (ELISA)
• Particle-enhanced Turbidimetric Immunoassay (PETIA)
• Colorimetric Assay
• Chemiluminescent Enzyme Immunoassay (CLIA)
• Liquid Chromatography Mass Spectrometry (LC-MS)

Breakup by End User:

• Hospital
• Diagnostic Laboratory
• Others

Breakup by Region:

• North America
• United States
• Canada
• Asia-Pacific
• China
• Japan
• India
• South Korea
• Australia
• Indonesia
• Others
• Europe
• Germany
• France
• United Kingdom
• Italy
• Spain
• Russia
• Others
• Latin America
• Brazil
• Mexico
• Others
• Middle East and Africa

Competitive Landscape:

The competitive landscape of the industry has also been examined along with the profiles of the key players being Abbott Laboratories, Beckman Coulter Inc. (Danaher Corporation), bioMérieux SA, BioPorto A/S, Bio-Rad Laboratories Inc., Enzo Biochem Inc., F. Hoffmann-La Roche AG, PerkinElmer Inc., Randox Laboratories Ltd., Siemens AG and Thermo Fisher Scientific Inc.

Key Questions Answered in This Report

1.What was the size of the global renal biomarkers market in 2024?

2.What is the expected growth rate of the global renal biomarkers market during 2025-2033?

3.What has been the impact of COVID-19 on the global renal biomarkers market?

4.What are the key factors driving the global renal biomarkers market?

5.What is the breakup of the global renal biomarkers market based on the biomarker type?

6.What is the breakup of the global renal biomarkers market based on the diagnostic technique?

7.What is the breakup of the global renal biomarkers market based on end user?

8.What are the key regions in the global renal biomarkers market?

9.Who are the key players/companies in the global renal biomarkers market?